About Us
Fund
Support
Return
Our Companies
left
About Us
Our Companies
Our DNA
Fund
Our Investment Strategy
Our Investors
Our Funds
Our Charity Fund
Support
Our Value Creation
Our Team and Network
Return
Return to Investors
Return to People
Return to Society
right
News
JOIN OUR TEAM
Investor Portal
Contact
NEWS
Our Latest News
ARCHIMED buys Cellese, a pioneering developer of growth factors and exosome-based skincare products
View All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
ARCHIMED’s MED II fund earns a 6x return on EUROLyser, its first exit
May
9,
2022
ARCHIMED sells health ingredients developer Fytexia to Associated British Foods
February
2,
2022
ARCHIMED buys CARSO, a leader in purity testing for pharma and other industries
December
16,
2021
ARCHIMED reaches agreement to sell Bomi Group to UPS
December
16,
2021
ARCHIMED buys a majority stake in SUANFARMA a leading manufacturer and distributor of active pharmaceutical and nutraceutical ingredients
November
18,
2021
ARCHIMED buys Cardioline, Europe’s leader in cardiology-focused telemedicine
November
17,
2021
<
1
2
3
4
5
6
…
14
>
368